Regenxbio Inc.
Clinical trials sponsored by Regenxbio Inc., explained in plain language.
-
One-Time gene therapy aims to halt devastating brain disease in toddlers
Disease control TerminatedThis study is testing a one-time gene therapy called RGX-121 in young children with a severe form of Hunter syndrome, a rare genetic disorder. The goal is to see if delivering a working gene directly to the brain can slow or stop the neurodevelopmental decline that current treatm…
Phase: PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
One-Shot gene therapy aims to treat devastating brain disease
Disease control TerminatedThis early-stage study is testing a one-time gene therapy called RGX-111 for people with MPS I, a rare genetic disease that damages the brain. The therapy is injected into the fluid around the brain and spine to deliver a working gene, hoping to help the brain produce a missing e…
Phase: PHASE1, PHASE2 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Tracking a potential lifeline: 5-Year study monitors boys after groundbreaking gene therapy
Disease control ENROLLING_BY_INVITATIONThis study is tracking boys for up to five years after they received an experimental gene therapy called RGX-202 for Duchenne muscular dystrophy (DMD). The main goal is to understand the long-term safety of the treatment and see if its benefits on muscle strength and movement las…
Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC